Medicsight PLC (AIM: MDST), industry leader in the development of Computer-Aided Detection (CAD) and image analysis software which assists in the early detection and diagnosis of disease, today announces the following restructuring of the Board effective on 19 March 2009.

Allan Rowley, currently Chief Financial Officer, becomes Chief Executive Officer while David Sumner, currently Chief Executive Officer, becomes Executive Chairman and Tim Paterson-Brown becomes a non-executive Director of Medicsight.

As Chief Executive, Allan will drive forward a revised plan focused on increasing revenues from existing products and streamlining all areas of the business.  This will be an ongoing process throughout the year. Allan also takes charge of the financial and operational performance of the Company.

Allan has been CFO of Medicsight since 2006.  Previously he worked for ComMedica Limited, a medical software company specialising in Picture Archiving & Communication System ("PACS") software.  Before joining ComMedica, Allan was revenue controller and the director of European Finance at Bea Systems, a NASDAQ-listed software company. Allan has several years of experience in public accounting in the United Kingdom and United States with Arthur Andersen and Ernst & Young, respectively.

Allan will be supported by Troy Robinson who has been promoted to Chief Financial Officer, although this is not initially a Board position.  Troy joined Medicsight in February 2007 as Group Financial Controller. Prior to this he was the Finance Manager for IVAX Pharmaceuticals and HP Foods. Troy is an associate of the Chartered Institute of Management Accountants.

As Executive Chairman, David Sumner will determine the overall strategy of the Company and will ensure that this strategy is agreed and effectively implemented.  In addition, David will lead the promotion of best practice and the highest standards of corporate governance.

David Sumner, Executive Chairman, commented: "We see 2009 as a pivotal year for the Company with the expected US and Japanese regulatory approvals around the corner. Medicsight, with its strong year end cash position of £18 million is in an excellent position to grow robust future revenues from these two strategic territories who currently use CT Colonography routinely in the detection and management of colorectal cancer.  These structural changes will enable me personally to focus on international developments and strategic partner discussions as part of our global drive for excellence and improvement of shareholder value.  Allan's remit is to continue to help increase revenues, embark on streamlining the Company, and maximising all efforts at this critical stage of the Medicsight's development.  We look forward to him working in this new capacity."

For further information:

Medicsight PLC
David Sumner
+44 (0)20 7605 7950
www.medicsight.com

Nomura Code
Juliet Thompson
+44 (0) 20 7776 1204
Jonathan Senior
+44 (0) 20 7776 1219

Media enquiries:

Notes to editors
Medicsight PLC is a UK-headquartered, research driven, leading developer of computer-aided detection (CAD) and image analysis software for the medical imaging market. The CAD software automatically highlights suspicious areas on computerised tomography (CT) scans of the colon and lung, helping radiologists to identify, measure and analyse potential disease and early indicators of disease. Medicsight's CAD software has been validated using one of the world's largest and most population diverse databases of verified patient CT scan data. Medicsight's ColonCAD^™ and LungCAD^™ software products are seamlessly integrated with the advanced 3D visualisation workstations of several industry-leading imaging equipment partners.

About Computer-Aided Detection
With increasingly sophisticated radiological imaging hardware such as Multi-Detector CT scanners, radiologists are facing a growing challenge in the amount of detailed patient image data that they must review for each patient examination. Some CT scan examinations generate as many as 2000 images per patient. Review of this data by the radiologist is not only time-consuming but also prone to error due to reader fatigue. CAD software can help the reviewing radiologist by analysing the image data and automatically highlighting suspicious regions of interest for closer inspection. Without CAD software some potential abnormalities or areas of disease may be overlooked. This can be critical for diagnosis and the management of patient outcomes as early detection of disease greatly increases the probability of successful treatment and a positive therapeutic outcome. In addition to supporting individual radiologists CAD also has the potential to help standardise CT interpretation across both individuals and institutions thereby supporting population based screening programmes.

About Medicsight's CAD software
Medicsight's ColonCAD^™ and LungCAD^™ software use an advanced CAD algorithm to analyse CT scans of the colon and lung and automatically highlight suspicious areas that may be indicators of disease. CAD may highlight areas easily overlooked by the reviewing radiologist, such as small lesions or regions that are hidden from view behind folds in the colon or normal structures and surrounding tissue in the lung.

Both CAD products seamlessly integrate with the advanced 3D visualisation platforms of industry-leading imaging equipment partners. The integrated systems provide sophisticated image viewing capabilities, including 3D reconstructed image data, with the added advantage of demonstrating automatic CAD findings to assist clinical end users in the detection and analysis of disease. This allows clinical end users to perform either a 'second read', where CAD findings are displayed to the user after completion of an initial review of the CT scan data, or a 'concurrent read' where CAD findings are displayed during the user's initial review of the original CT scan images.

Since inception, Medicsight has developed close and lasting relationships with some of the world's foremost clinicians in product related areas. This provides the Company with a wealth of clinical expertise and dedicated clinical research to support ongoing product development. Medicsight also collaborates with a number of leading academic institutions and clinical research programmes worldwide to develop the Company's comprehensive database of population diverse verified patient CT scan data, thus allowing Medicsight's products to be validated to the highest possible standards.